中位生存时间为43个月。
这10例患者的中位生存时间为19个月。
中位生存时间5月。
术后6个月，12个月生存率及中位生存时间显著提高。
Survival of 6, 12 months and middle survival time were improved.
根治性切除和非根治性切除病人的中位生存时间分别为2 6个月和9个月。
The medium survival time of radical resection and non-radical resection was 26 months and 9 months respectively.
结果根治性切除组、姑息性切除组和未切除肿瘤组中位生存时间分别为13、8和5个月。
Results The medial survival time of radical resection, palliative section and exploratory laparotomy were 13, 8 and 5 months, respectively.
接受放疗病人的中位生存时间是17.5个月，而接受手术病人的中位生存时间是16.4个月。
The median survival time for patients treated with radiation was 17.5 months, compared to 16.4 months for those who had surgery.
结果：本组盆腔淋巴结阴性患者的五年总体生存率为82 0 %，中位生存时间10 0 0月。
Results: the overall 5-year survival of the patients was 82.0% and the median survival time was 100.0 months.
方法建立小鼠系统性白念珠菌感染模型，观察给药后小鼠中位生存时间，并检测给药后小鼠肾脏菌落形成单位计数。
Methods a mouse model of disseminated candidiasis was established and the survival rate and median survival time after administration of agent were detected.
其中19例单纯卵巢转移患者的中位生存时间31个月，43例卵巢合并其他部位转移患者的中位生存时间21个月。
The median survival time of 19 patients with simple ovary metastasis was 31 months, while that of 43 patients with ovary and other organ metastasis was 21 months.
长期的寒冷迫使许多加拿大人在屋子里跑来跑去，而一位被称为“冰棒教授”的研究者在此期间发现人类可以在严寒中成功坚持生存很长时间。
During a cold stretch that had many Canadians scurrying indoors, a researcher known as "Professor Popsicle" has found humans can successfully spend days on end in the bitter cold.
肝切除术、胆管取癌栓及胆道引流术病人术后生存时间为5 ~ 4 6个月，中位生存期为2 3 5个月。
After hepatectomy with embolectomy and biliary duct drainage, the survival time was 5-46 months and the survival median time was 23.5 months.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
应用推荐